54Clark and John Q. Trojanowski. McGraw-Hill 2000 pp. 147-156２）Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y : Visualization of Aβ42 (43) and Aβ40 in senile plaques with end-specific Aβ-monoclonals : Evidence that an initially deposited species is Aβ42 (43). Neuron 13 : 45-53, 1994 ３）Iwatsubo T, Mann DMA, Odaka A, Suzuki N, Ihara Y : Amyloid β protein (Aβ) deposition : Aβ42 (43) precedes Aβ40 in Down syndrome. Ann Neurol 37 : 294-299, 1995４）Iwatsubo T, Saido TC, Mann DMA, Lee VM-Y, Trojanowski JQ : Full-length amyloid-β (1-42 (43)) as well as amino-terminally modified and truncated amyloid-β42 (43) deposit in diffuse plaques. Am J Pathol 149 : 1823-1830, 1996５）Tomita T, Maruyama K, Saido TC, Kume H, Shinozaki K, Tokuhiro S, Capell A, Walter J, Grüenberg J, Haass C, Iwatsubo T, Obata K : The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid β protein ending at the 42nd (or 43rd) residue. Proc Natl Acad Sci USA 94 : 2025-2030, 1997 ６）Tomita T, Tokuhiro S, Hashimoto T, Aiba K, Saido TC, Maruyama K, Iwatsubo T : Molecular dissection of domains in mutant presenilin 2 that mediate overproduction of amyloidogenic forms of amyloid β peptides : Inability of truncated forms of PS2 with familial Alzheimer’s disease mutation to increase secretion of Aβ42. J Biol Chem 273 : 21153-21160, 1998７）Tomita T, Takikawa R, Koyama A, Morohashi Y, Takasugi N, Saido TC, Maruyama K, Iwatsubo T : C terminus of presenilin is required for overproduction of amyloidogenic Aβ42 through stabilization and endoproteolysis of presenilin. J Neurosci 19 : 10627-10634, 1999８）Takasugi N, Tomita T, Hayashi I, Tsuruoka M, Niimura M, Takahashi Y, Thinakaran G, Iwatsubo T : The role of presenilin cofactors in the γ-secretase complex. Nature 422 : 438-441, 2003９）Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH : Toward defining the preclinical stages of Alzheimer’s disease : Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7 : 280-292, 201110）Iwatsubo T, Iwata A, Suzuki K, Ihara R, Arai H, Ishii K, Senda M, Ito K, Ikeuchi T, Kuwano R, Matsuda H, Sun CK, Beckett LA, Petersen RC, Weiner MW, Aisen PS, Donohue MC : Japanese and North American Alzheimer’s Disease Neuroimaging Initiative studies : harmonization for international trials. Alzheimers Dement 14 : 1077-1087, 201811）Haeberlein SB, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, Dent G, Hansson O, Harrison K, von Hehn C, Iwatsubo T, Mallinckrodt C, Mummery CJ, Muralidharan KK, Nestorov I, Nisenbaum L, Rajagovindan R, Skordos L, Tian Y, van Dyck CH, Vellas B, Wu S, Zhu Y, Sandrock A : Two randomized phase 3 studies to evaluate aducanumab in early Alzheimer disease. J Prev Alzheimers Dis 9 : 197-210, 202212）van Dyck CH, Swanson CJ, Aisen P, Bateman R, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T : Lecanemab in early Alzheimer’s disease. N Engl J Med 388 : 9-21, 202313）Sperling RA, Donohue MC, Raman R, Rafii M, Johnson K, Masters C, Van Dyck C, Iwatsubo T, Marshall G, Yaari R, Mancini M, Holdridge KC, Case M, Sims J, Aisen PS : Trial of solanezumab in preclinical Alzheimer’s disease. 文 献１）Iwatsubo T : Amyloid deposits and plaque formation. Neurodegenerative Dementias. Edited by Christopher M.
元のページ ../index.html#56